Moderna Stock Price, News & Analysis

Moderna, Inc. (NASDAQ:MRNA) has announced a deal with Japan's Ministry of Health to supply an additional 70 million doses of its COVID-19 booster vaccine in the second half of 2022. This agreement could increase the total contracted doses for Japan from 93 million to 163 million. The vaccine has received special approval for use in preventing COVID-19, with booster doses recommended for adults six months after the second dose. The agreement is contingent upon securing the necessary budget from the Ministry.

Moderna (Nasdaq:MRNA) announced the first participant has been dosed in its Phase 1 trial (HVTN 302) for an experimental HIV trimer mRNA vaccine (mRNA-1574). This multicenter, randomized trial aims to assess safety and immunogenicity in approximately 100 HIV-negative adults aged 18 to 55. Moderna's strategy involves using mRNA to induce protective HIV neutralizing antibodies. The trial is sponsored by the Division of AIDS at NIAID and aims to advance Moderna's capabilities in mRNA technology for HIV prevention.

Moderna has initiated a Phase 2 study of its Omicron-specific bivalent booster candidate (mRNA-1273.214), which combines mRNA-1273.529 and the original COVID-19 vaccine, mRNA-1273. The trial aims to enroll approximately 375 participants across 20 sites in the U.S. and will assess the immunogenicity, safety, and reactogenicity of the booster in adults. The study marks an extension of prior research and aligns with Moderna's commitment to adapt vaccines for emerging variants. Results will be shared with public health authorities ahead of the upcoming booster season.

Moderna, Inc. (NASDAQ:MRNA) will host its virtual Vaccines Day for analysts and investors on March 24, 2022, at 8:00 a.m. ET. The event will feature management presentations and insights from key opinion leaders regarding Moderna's mRNA vaccines and important developmental considerations. A live webcast will be accessible in the Investors section of the Moderna website, with a replay available for one year thereafter. Moderna has evolved to become a leading mRNA therapeutics and vaccines company, contributing significantly to pandemic efforts with its COVID-19 vaccine.

Moderna has unveiled a new global public health strategy through four key initiatives aimed at advancing mRNA vaccines for infectious diseases. The company plans to develop vaccines targeting 15 priority pathogens by 2025. Additionally, mRNA Access will allow researchers worldwide to utilize Moderna's mRNA technology. The company has also expanded its patent pledge, ensuring no enforcement in 92 low- and middle-income countries. Notably, Moderna will establish its first mRNA manufacturing facility in Kenya, investing up to $500 million to produce up to 500 million doses annually.

Moderna is investing up to $500 million to establish its first mRNA manufacturing facility in Kenya, aiming to produce up to 500 million doses of vaccines annually for the African continent. This initiative, made in partnership with the U.S. Government, focuses on enhancing local manufacturing capabilities to ensure equitable access to vaccines. The facility will initially handle drug substance manufacturing and may expand to include fill/finish services. Moderna's commitment is a significant step towards improving global health equity and preparing for future health crises.

Moderna (NASDAQ:MRNA) announced plans to create an Enterprise Solutions Hub in Atlanta, Georgia, supporting the U.S., Canada, and Latin America. The hub aims to hire 150-200 employees over two years, focusing on finance, human resources, procurement, and digital functions. CEO Stéphane Bancel highlighted the need for business services aligned with skilled talent. The Atlanta hub complements an existing hub in Warsaw, Poland. Moderna anticipates expanding its commercial subsidiaries globally, emphasizing the strategic choice of Atlanta for its diverse and skilled workforce.

Moderna, Inc. (NASDAQ:MRNA) announced its schedule for three upcoming investor conferences in March 2022. The events include the Cowen 42nd Annual Health Care Conference on March 9 at 9:10 a.m. ET, the Barclays Global Healthcare Conference on March 15 at 1:30 p.m. ET, and the Oppenheimer 32nd Annual Healthcare Conference on March 17 at 10:00 a.m. ET. Live webcasts will be available on Moderna's investor website, with replays accessible for 30 days post-event. Moderna continues to lead in mRNA therapeutics and has received recognition for its contributions to COVID-19 vaccine development.

Moderna has received a positive opinion from the EMA's CHMP to expand the conditional marketing authorization for its COVID-19 vaccine, Spikevax, to include children aged 6-11. This follows a successful Phase 2/3 study involving over 4,000 children, demonstrating non-inferior antibody responses compared to 18-25 year-olds. The European Commission will decide on the authorization. Additionally, the EMA updated the recommendation for booster doses, now allowing a booster after three months instead of six, and heterologous booster combinations.